ABOS (Acumen Pharmaceuticals) Other Current Receivables: $0.77 Mil (As of Mar. 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.77
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals Other Current Receivables?

Acumen Pharmaceuticals ABOS +17.37% 34 Other Current Receivables is $0.77 Mil as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Acumen Pharmaceuticals's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.77 Mil.

Acumen Pharmaceuticals's quarterly Other Current Receivables increased from Sep. 2025 ($0.38 Mil) to Dec. 2025 ($0.63 Mil) and increased from Dec. 2025 ($0.63 Mil) to Mar. 2026 ($0.77 Mil).

Acumen Pharmaceuticals's annual Other Current Receivables increased from Dec. 2023 ($0.23 Mil) to Dec. 2024 ($0.35 Mil) and increased from Dec. 2024 ($0.35 Mil) to Dec. 2025 ($0.63 Mil).

Acumen Pharmaceuticals Other Current Receivables Related Terms

Acumen Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals Other Current Receivables Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.00 0.00 0.23 0.35 0.63

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.32 0.38 0.63 0.77
ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.77 Mil mean?
Acumen Pharmaceuticals (ABOS) has a Other Current Receivables of $0.77 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Acumen Pharmaceuticals and its competitors.
Is Acumen Pharmaceuticals' Other Current Receivables too high?
Acumen Pharmaceuticals' current Other Current Receivables is $0.77 Mil. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' Other Current Receivables compare to YDES and PYXS?
Acumen Pharmaceuticals' Other Current Receivables of $0.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current Other Current Receivables is $0.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current Other Current Receivables of $0.77 Mil. The current Other Current Receivables is $0.77 Mil. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current Other Current Receivables is $0.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77
Price